SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Helix Acquisition Corp. (Nasdaq – HLXA)

BALA CYNWYD – November 3, 2021 /Access Wire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Helix Acquisition Corp. (“HELIX” or the “Company”) (Nasdaq – HLXA) for possible breaches of fiduciary duty and other violations of federal and state law in connection with an agreement pursuant to which HELIX, a special purpose acquisition company, will combine with MoonLake Immunotherapeutics AG, (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, and result in MoonLake becoming a publicly-listed company. Under the terms of the agreement, HELIX shareholders will retain ownership of only 18.5 % of the combined company.

The investigation concerns whether the HELIX Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of ownership interest in the combined company.

If you own shares of HELIX stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.